|
|
Reference
|
|
  
|
Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S. (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 376(11): 1015-1026
|
|
|
Bot, I., Blank, C.U., Boogerd, W., Brandsma, D. (2013) Neurological immune-related adverse events of ipilimumab. Practical Neurology, 13(4): 278-280
|
|
|
Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén, F.O., Havel, L. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373(2): 123-135
|
|
|
Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R., Carpentier, A.F. (2017) Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. European Journal of Cancer, 73: 1-8
|
|
|
Decatris, M.P., o'Byrne Kenneth, J. (2016) Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. Future Oncology, 12(15): 1805-1822
|
|
|
Feng, S., Coward, J., McCaffrey, E., Coucher, J., Kalokerinos, P., o’Byrne Ken (2017) Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 12(11): 1626-1635
|
|
|
Graus, F., Saiz, A., Dalmau, J. (2010) Antibodies and neuronal autoimmune disorders of the CNS. Journal of Neurology, 257(4): 509-517
|
|
|
Kao, J.C., Liao, B., Markovic, S.N., Klein, C.J., Naddaf, E., Staff, N.P., Mauermann, M.L. (2017) Neurological Complications Associated with Anti-Programmed Death 1 (PD-1) Antibodies. JAMA Neurology, 1(10): 1216-1216
|
|
|
Liao, B., Shroff, S., Kamiya-Matsuoka, C., Tummala, S. (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology, 16(4): 589-593
|
|
|
Maur, M., Tomasello, C., Frassoldati, A., Dieci, M.V., Barbieri, E., Conte, P. (2012) Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma. Journal of Clinical Oncology, 30(6): e76-e78
|
|
|
Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., Tykodi, S.S., Sosman, J.A., Procopio, G., Plimack, E.R., Castellano, D., Choueiri, T.K., Gurney, H., Donskov, F. (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 373(19): 1803-1813
|
|
1
|
Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C.U., Hamid, O., Mateus, C. (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 372(26): 2521-2532
|
|
|
Salam, S., Lavin, T., Turan, A. (2016) Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Reports, bcr2016215012-bcr2016215012
|
|
|
Seiwert, T.Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J.P., Chow, L.Q. (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncology, 17(7): 30066-30069
|
|
|
Spain, L., Walls, G., Julve, M., o'Meara K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M., Rees, J., Larkin, J. (2016) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature. Annals of Oncology, 28: mdw558-mdw558
|
|
|
Wei, X., Walia, V., Lin, J.C., Teer, J.K., Prickett, T.D., Gartner, J., Davis, S., Stemke-Hale, K., Davies, M.A., Gershenwald, J.E., Robinson, W., Robinson, S., Rosenberg, S.A., Samuels, Y. (2011) Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nature Genetics, 43(5): 442-446
|
|
|
Wilgenhof, S., Neyns, B. (2011) Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Annals of Oncology, 22(4): 991-993
|
|
|
Williams, T.J., Benavides, D.R., Patrice, K., Dalmau, J.O., de Ávila, A.L.R., Le, D.T., Lipson, E.J., Probasco, J.C., Mowry, E.M. (2016) Association of Autoimmune Encephalitis with Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. JAMA Neurology, 73(8): 928-928
|
|
|
|
|